Dynatrace (DT) Q2 2027 Earnings Call Transcript

Dynatrace reported Q2 revenue of $580 million, up 17% year over year, and a 32% non-GAAP operating margin, nearly 200 basis points above the high end of guidance; diluted non-GAAP EPS was $0.54, $0.05 above the high end. Net new ARR was $70 million, flat year over year and high-single-digit millions below expectations as large enterprise expansions shifted into the second half; trailing 12-month net retention declined 1 point sequentially to 109%. The company maintained standalone FY2027 ARR growth guidance of 15.5%-16.5%, raised standalone revenue outlook by about 50 basis points at the midpoint, and authorized an additional $1 billion in buybacks, while forecasting 175 basis points of operating-margin dilution from Arize and lower EPS partly due to its $1.4 billion convertible note issuance.

Analysis

DT’s key debate is conversion, not demand: high consumption and rapid log growth have yet to translate consistently into booked expansion. The company also acknowledged that higher customer volumes bring additional discounts, so telemetry growth should not be modeled as a one-for-one ARR or margin driver. The bullish case is that the large second-half renewal cohort converts usage into larger commitments; the bear case is that complex consolidation decisions and bespoke pricing defer or dilute that conversion.

Near term, Q3 and especially Q4 carry execution risk: management’s back-half confidence rests on renewals and expansions, with most renewal activity concentrated in Q4. A further slip could pressure organic growth expectations even if consumption remains healthy. Arize adds reported ARR but also dilutes operating margin; standalone performance is the cleaner signal. The convertible issuance further reduces per-share leverage to operating upside. Conversely, AI-agent monetization and the CrowdStrike relationship could strengthen log adoption, though revenue contribution and customer uptake remain unverified.

Contrarian read: the weak net-new ARR quarter may be timing rather than demand deterioration, but investors risk treating usage indicators as already-earned ARR. For the next 1–3 months, watch Q3 organic net-new ARR, NRR, and evidence that agent usage converts to paid consumption. Over 6–18 months, assess whether Arize cross-sell and log growth yield durable expansion without material discounting. Falsify the recovery thesis if Q3/Q4 expansions fail to recover or NRR declines further; confirmation requires improving organic bookings and retention, not consumption claims alone.

Key Decisions for Investors

• Keep DT at neutral/benchmark exposure pending Q3 evidence; do not add solely on consumption or AI-preview metrics. Reassess after reported organic net-new ARR and NRR clarify whether delayed expansions are closing.
• For investors seeking upside, consider a small, defined-risk DT call spread only after Q3 shows organic net-new ARR improvement and NRR stabilization; avoid paying for a Q4 recovery before those indicators arrive.
• Track Q4 renewal conversion, realized pricing/discounting, and paid adoption of agents and Arize. A miss on expansion conversion would weaken the thesis even if log volumes remain strong.
• Treat CRWD partnership commentary as a watch item rather than a standalone CRWD trade: verify customer wins, routed-log adoption, and commercial contribution before underwriting material incremental revenue.